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Background: The Gram-negative bacterium Chlamydia pneumoniae (Cpn) is the leading intracellular human
pathogen responsible for respiratory infections such as pneumonia and bronchitis. Basic and applied research in
pathogen biology, especially the elaboration of new mechanism-based anti-pathogen strategies, target discovery
and drug development, rely heavily on the availability of the entire set of pathogen open reading frames, the
ORFeome. The ORFeome of Cpn will enable genome- and proteome-wide systematic analysis of Cpn, which will
improve our understanding of the molecular networks and mechanisms underlying and governing its
pathogenesis.
Results: Here we report the construction of a comprehensive gene collection covering 98.5% of the 1052 predicted
and verified ORFs of Cpn (Chlamydia pneumoniae strain CWL029) in GatewayW ‘entry’ vectors. Based on genomic
DNA isolated from the vascular chlamydial strain CV-6, we constructed an ORFeome library that contains 869
unique GatewayW entry clones (83% coverage) and an additional 168 PCR-verified ‘pooled’ entry clones, reaching
an overall coverage of ~98.5% of the predicted CWL029 ORFs. The high quality of the ORFeome library was verified
by PCR-gel electrophoresis and DNA sequencing, and its functionality was demonstrated by expressing panels of
recombinant proteins in Escherichia coli and by genome-wide protein interaction analysis for a test set of three Cpn
virulence factors in a yeast 2-hybrid system. The ORFeome is available in different configurations of resource stocks,
PCR-products, purified plasmid DNA, and living cultures of E. coli harboring the desired entry clone or pooled entry
clones. All resources are available in 96-well microtiterplates.
Conclusion: This first ORFeome library for Cpn provides an essential new tool for this important pathogen. The
high coverage of entry clones will enable a systems biology approach for Cpn or host–pathogen analysis. The high
yield of recombinant proteins and the promising interactors for Cpn virulence factors described here demonstrate
the possibilities for proteome-wide studies.
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Bacteria are one of the most common causes of commu-
nity acquired pneumonia. The Gram-negative bacterium
Chlamydia pneumoniae (Cpn) is a prominent human
pathogen responsible for respiratory infections like pneu-
moniae and bronchitis [1,2]. Moreover, the involvement of
Cpn in other human diseases such as atherosclerosis [3],
reactive arthritis [4], and myocarditis [5], or the associ-
ation between Cpn infection and lung cancer [6], makes
this pathogen an important risk factor in human disease.
Furthermore, the bacterium’s obligate intracellular life-
cycle can facilitate establishment of chronic persistent
infections and/or reinfections following primary infection,
thus posing a risk for chronic inflammatory disease [7,8].
About half of the 1052 open reading frames (ORFs) of
Cpn encode proteins without any known function [9]. A
flexible gene collection that contains all Cpn genes is a pre-
condition to identify new or additional protein functions,
e.g. through the discovery of possible interaction partners
or the production of recombinant proteins for enzymatic
assays or to test their influence on gene expression.
In recent years, numerous comprehensive gene collections
termed ORFeomes have been constructed for organisms ran-
ging from bacteria [10] to human [11]. The use of recombi-
national cloning, or GatewayW cloning [12,13], as a cloning
strategy lends itself to diverse applications, from whole-
genome sequencing to downstream ‘omics’ approaches.
Cloning methods using traditional restriction endonucleases
are too cumbersome and inefficient when hundreds of genes
have to be cloned and analyzed further. Recombinational
cloning enables high-throughput and large-scale ‘omics’
applications [14] with a wide choice of vectors, including
Yeast Two-Hybrid (Y2H) vectors [15], Mammalian Two-
Hybrid vectors [16], and ORF expression vectors. The avail-
ability of an ORFeome should accelerate systematic and
organism-wide molecular research, improving our under-
standing of complex molecular networks governing virulence
factors and pathogenesis.
Here we report the construction of a comprehensive
gene collection covering 98.5% of the 1052 predicted and
verified ORFs of Cpn (Chlamydia pneumonia strain
CWL029) in GatewayW ‘entry’ vectors. This platform is
highly flexible because the genes can easily be shuttled
into any type of ‘destination’ vector to create an expres-
sion library for genome-wide studies such as Y2H map-
ping of novel Cpn protein–protein interactions (PPIs).
Also, new target genes involved in host interactions can
be identified. Array-based methods are already established
to screen hundreds of ORFs for possible Cpn–human PPIs
[17]. We verified the quality of the created platform by
PCR amplification and DNA sequencing of entry clones.
To demonstrate its functionality we performed a genome-
wide Y2H analysis with three different Cpn genes: the
EUO gene is a transcriptional regulator, and the flhA andfliF genes encode orthologs of flagellar proteins and are
probable members of the Type-III secretion apparatus.
Furthermore, to establish the suitability of the ORFeome
for protein or proteome research, we demonstrated ex-
pression of panels of GST-tagged Cpn fusion proteins in
E. coli. This newly generated, adaptable platform offers
numerous advantages for high-throughput genomic and
proteomic investigations into the molecular mechanisms
and pathways involved in Cpn infection.Results
The overall strategy we employed for construction and
characterization of the ORFeome of C. pneumoniae is
summarized in Figure 1.The ORFeome of C. pneumoniae represents 98.5% of the
predicted ORFs
For construction and characterization of the Cpn ORFeome,
we employed the same strategy as we used in developing the
first Staphylococcus aureus ORFeome [10]. For amplification
of each Cpn ORF, the primers were designed to generate
full-length attB1 and attB2 sites. To allow for the production
of C-terminal fusion proteins, which can be expressed in ap-
propriate destination vectors, the stop codons of each ORF
were omitted in the reverse primers. Shine-Dalgarno (50-
GAAGGAGATA-30) and Kozak (50-ACCATG-30) consensus
sequences were incorporated into the forward primers such
that the ATG in the Kozak sequence is in frame with the
attB1 site, thus allowing N-terminal fusion proteins to be
produced from destination vectors that contain N-terminal
tags. After preparation of all Cpn PCR products for Gate-
wayW cloning, a set of 300 arbitrarily chosen samples were
analyzed by gel electrophoresis. All samples, apart from two
exceptions, showed a DNA band of the expected size.
The PCR products were inserted into the GatewayW-
compatible vector pDONRTM/Zeo (Invitrogen, Carlsbad,
CA, USA) by BP-cloning. The products resulting from
site-specific recombination were transformed into E.
coli. A portion of the cells was plated on solid medium
containing ZeocinTM, and the remainder was used to in-
oculate liquid medium containing ZeocinTM to generate
bacterial stocks of pooled entry clones for long-term
freezer storage. Up to five single colonies from each
plate were tested in a colony-PCR with pDONRTM/Zeo-
specific primers. The resulting PCR products were
detected by gel electrophoresis. Transformants which
had an insert of the expected size were picked and
grown in liquid medium containing ZeocinTM to gener-
ate bacterial glycerol stocks for long-term freezer stor-
age. By this approach we obtained 869 transformants
carrying the correct insert, which represents 83% of the
1052 predicted ORFs. Using both the positive single-
colony glycerol stocks to inoculate liquid medium
Figure 1 Overview of the construction of the C. pneumoniae ORFeome. The PCR products of the amplified ORFs were used in the first step
of a BP reaction to create an Entry library, followed by PCR and sequencing for technical confirmation. For expression of recombinant proteins,
the Entry library was used for LR reactions. Additionally, an Y2H library was generated for validation by functional analysis.
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those ORFs for which no positive single-colony isolate
was obtained, cultures were grown in 96-well plates
and plasmid DNAs were prepared and used for PCR.
For an additional 168 samples, an insert of the size
expected for the ORF was observed. In total, we found
869 single entry clones and 168 ‘pooled’ entry clones,
giving a resource of 1,037 entry clones (98.5% of the
predicted ORFs). The remaining 1.5% yielded a PCR
product of ~300 bp, derived from empty pDONRTM/
Zeo vector. As reported by Brandner et al. [10], we expect
there to be additional positive single clones in the liquid
glycerol stocks of the pooled entry clones. The single-
colony glycerol stocks, the glycerol stocks of the pooled
transformants, and the purified plasmid clones together
constitute the ORFeome of Chlamydia pneumoniae.The identity of all single entry clones was validated by
DNA sequencing
To verify that the inserted ORFs are in the correct reading
frame and indeed correspond to the assigned identity, we
took all plasmid preparations of the positive single col-
onies and subjected them to sequencing with a
pDONRTM/Zeo-specific forward primer. Ninety percent
of the positive single clones were found to be correctly
inserted, and a BLAST search of each sequence against
the Cpn CWL029 genome (NCBI Refseq: NC_000922.1)
confirmed the identity of each ORF. Almost all of the
remaining 10% of positive single clones were found to
have mutations in the binding region of the gene-specificforward primer, resulting in frameshift or missense muta-
tions. Despite the presence of these mutations in the pri-
mer regions, the identity of these clones was confirmed
by BLAST searches.
Proteome-wide recombinant gene expression is possible
by using the Cpn ORFeome
In order to examine all ORFs at the protein level we
decided to shuttle randomly choosen single clones into
the pDESTTM15 vector (Invitrogen) designed to make a
fusion protein with a GST-Tag. The resulting products
were transformed into the BL21(DE3) protein expres-
sion strain of E. coli. Successful recombination of the
choosen single clones was shown by PCR of single col-
onies obtained following transformation. For proteome-
wide studies, the availability of recombinant proteins is
the main bottleneck; therefore, we produced a panel of
recombinant proteins directly from an arbitrarily
chosen test set of 10 clones taken from the ORFeome
cloned in pDESTTM15 vector (Invitrogen). The clones
were used to transform the BL21(DE3) protein expres-
sion strain of E. coli, and after induction of protein ex-
pression with IPTG, the cells were lysed and 2.5 μg
total protein from the crude lysates were separated and
analyzed on a protein gel with coomassie staining. As
seen from the coomassie and western blot analysis in
Figure 2, all 10 of the ORFs were highly expressed and
a range of protein sizes from small to large was pro-
duced. In summary, robust expression of all 10 GST-
tagged proteins demonstrates the functionality of the
ORFeome.
Figure 2 Recombinant protein expression in E. coli. Ten GST-tagged C. pneumoniae recombinant proteins (A) were loaded in equal amounts
of total protein from crude lysates in each lane and subjected to SDS-PAGE and coomassie staining (B). Additionally the same crude lysates were
examined by SDS-PAGE and western blotting (C). The given protein sizes are already calculated for GST-fusion proteins. The arrows indicate the
recombinant proteins.
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several new interacting proteins for promising bait
molecules
Proteins are the workhorses of the cellular machinery.
They often function in huge protein complexes where the
action of single proteins is mediated through their binding
to other proteins in the complex. Moreover, there often
exists cross-talk, mediated by interactions, between differ-
ent protein complexes. Indeed, in all signal transduction
pathways, the signal would become lost without functional
PPIs [18]. Therefore, to understand a biological system,
such as the relatively uncharacterized Cpn organism, it is
essential to investigate novel protein interactions.
For that purpose and to demonstrate the new capabil-
ities of the Cpn ORFeome, we performed three individual
ORFeome-wide Y2H screens. As bait proteins, the Cpn
genes flhA (Cpn0363; type III secretion system protein),fliF (Cpn0860; type III secretion system protein), and EUO
(Cpn0561; hypothetical protein) were cloned in the Y2H
pBD-Gate2 [15] vector. For all three bait molecules no
autoactivation of reporter genes could be observed. A prey
library was created by pooling all plasmid preparations of
entry clones and transferring them by LR reaction into
pAD-Gate2 [15]. Randomly chosen clones were selected
for colony-PCR with pAD-Gate2-specific forward and re-
verse primers. The 20 clones showed different-sized PCR
bands, from 400 bp up to 2.2kbp.
In all three screens, at least 1.7 x 105 primary colonies,
representing the same number of examined PPIs, were
observed. On interaction-selective plates, we detected
(and sequenced) two new interaction partners each for
flhA and fliF. For the hypothetical protein EUO, four
interactors were detected. These newly identified inter-
action partners are summarized in Table 1.
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In this work we described the construction of a comprehen-
sive and flexible gene collection of Chlamydia pneumoniae.
This ORFeome consists of 869 ORFs maintained as
homogeneous plasmid DNAs purified from single colonies
plus 168 ORFs purified from separate ‘pools’ of entry
clones. This coverage of 98.5% of all predicted Cpn ORFs
is similar to the coverage reported for other bacterial
ORFeomes [10,19-21]. Such ORFeomes offer a flexible
resource with which to undertake functional genomic
studies, including high-throughput screens [22-24]. In our
own laboratory we have successfully produced protein
arrays/chips [17] whereon thousands of proteins can be
tested against other proteins or peptides. The described
Cpn ORFeome is the basis for functional high-throughput
analysis of this organism, providing a flexible tool for
quick and efficient genome-wide examination and
discovery.
We assessed the quality of the ORFeome by PCR and
agarose gel-electrophoresis of all the entry clones
obtained. Sequencing all positive single clones confirmed
the identity of the entry clones. To minimize the occur-
rence of PCR-induced mutations, we optimized the PCR
conditions, used a proofreading-capable DNA polymerase,
and kept the number of amplification cycles low. Func-
tional validation was done by recombinant protein pro-
duction and PPI analysis using the Y2H system. According
to our previous work [10], we did not purify the first PCR
products, because it does not minimize the possibility of
primer dimers created by the secondary attachment pri-
mers. These primer dimers are the putative reason for the
existence of samples for which no positive single clone
could be found. In the present study we spot-tested 300
arbitrarily chosen first PCR products. Almost all products
delivered a PCR band of the expected size. In addition, we
examined PCR samples of negative candidates (no positive
single clone) where the first-generated PCR product deliv-
ered, like the other samples examined, a strong PCR band.Table 1 Results of Y2H Analysis
BAIT Identified Interactor
type III secretion system
protein flhA CPn0363
secretion chaperone sycE
type III secretion system
protein flhA CPn0363
methyltransferase ada CPn
type III secretion system
protein fliF CPn0860
type III Secretion protein fl
type III secretion system
protein fliF CPn0860
hypothetical protein CPn0
EUO CPn0561 hypothetical protein EUO
EUO CPn0561 hypothetical protein CPn0
EUO CPn0561 hypothetical protein CPn1
EUO CPn0561 PTS phosphocarrier proteinIn most cases we could isolate positive candidates by in-
vestigating up to 20 clones of one reaction, affording a
way to clone single genes but not hundreds of genes. We
failed to produce PCR products for 15 ORFs. This could
be due to possible errors in annotation of the CWL029
genome or, more likely, because of nucleotide differences
between our Cpn isolate and the sequenced CWL029 gen-
ome or for technical reasons related to primer design and
effectiveness specific to each missing ORF. The single
entry clones are of higher quality than the pools of entry
clones because they are homogeneous, and LR reactions
performed subsequently with the pure clones will be more
efficient. However, for reasons of economy and because of
time constraints, it was not possible to screen every colony
to obtain a pure isolate of the appropriate ORF-containing
entry clone. However, we expect that additional positive
single transformants are present in the liquid glycerol
stocks. In future work, this version of the Cpn ORFeome
may be extended by isolating more positive single clones.
Ninety-seven positive single clones (10% of the positive
single clones) failed validation by DNA sequencing. Al-
most all of the affected genes harbor a mutation in the
binding region of the primary forward primer, resulting in
frameshift mutations. However, this type of problem could
be solved by using primers of higher quality than the used
Mass Spectrometry checked primers in this work. Another
solution could be to re-order the 10% defective primers
and re-clone the defective clones or to correct the muta-
tions by using mutagenesis kits. Although these genes are
not in frame with the commonly used GatewayW destin-
ation vectors, there is the possibility of transferring them
to other vectors having the appropriate reading frame.
Alternatively, there already exist reading-frame independ-
ent vectors suitable for GatewayW cloning [15,16]. The use
of such vectors would increase the overall coverage of
positive single clones.
The present work provides the first nearly complete
ORFeome of Cpn. Production of recombinant proteinsScreen efficiency = tested
binary PPI combinations
CPn0325 1.7*105
0596 1.7*105
iN CPn0704 3.6*105
693 3.6*105
CPn0561 4.2*105
423 4.2*105
007 4.2*105
Hpr ptsH CPn0037 4.2*105
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known GST fusion tag. This tag could be used for fur-
ther protein purification or affinity studies such as GST
Pull-Down for validation of protein–protein interactions.
We successfully produced fusion proteins of ten ran-
domly chosen clones. ORFeome-wide protein chips
already exist [25-27] and could be applied to our Cpn
collection for analyzing not only protein–protein inter-
actions, but also the ability of proteins to bind to small
molecules as well as other proteins. A special field in the
case of Cpn would be the use of proteome chips in drug
and drug target discovery, because such chips can pro-
vide a variety of systems for detecting drug–protein
interactions among all proteins. The technique for
proteome chips already exists in our working group, and
was verified by finding a small epitope to a known anti-
gen, another type of protein–peptide interaction [17].
As a validation of our interaction screen, first we used
FlhA, a Type-III secretion apparatus member. The Y2H
screen identified the Type-III secretion chaperone sycE
as an interaction partner. SycE is related to the class-I
chaperones involved in binding of effector proteins dur-
ing the secretion process. Since FlhA is located in the
inner membrane and is involved in flagellar protein se-
cretion, it is possible that SycE interacts with FlhA dur-
ing the export of flagellar or other proteins. Supporting
this finding, it was previously reported that another
chaperon, FliJ, is also an interaction partner of FlhA
[28]. We also identified the methyltransferase ada, which
in E. coli is known to be involved in the repair of DNA
damage induced by methylating agents. The link be-
tween ada and the Type-III secretion apparatus is un-
known, but it is worth mentioning that chlamydia
transports other methyltransferases to influence host
gene expression via Type-III secretion [29].
The second tested bait protein, FliF, is a member of
the MS ring of the Type-III injectisome [30]. FliF is a
previously described binding partner of FlhA [31], but
we could not detect this interaction. Although, the Y2H
system is a powerful system to detect PPIs, nevertheless
not all interactions can be detected within a single
screen and further reasons could be loss of interaction
due to the fusion with the yeast GAL4 protein domain,
or the requirement that the interaction between bait and
prey are obliged to happen in the nucleus of yeast cells.
There are a couple of reasons leading to false-negatives
in the Y2H system, a drawback actually existing in all
PPI-methods. On the other hand, we identified FliN, a
putative C-ring member [30], as an interaction partner
of FliF.
Our third bait protein was EUO, a chlamydial protein
expressed early in the developmental cycle. EUO is able
to bind to AT-rich sequences [32] and also has been
shown to have a histone H1-specific protease activity[33]. While the potential interaction partners of EUO
are not known, we identified EUO itself, two hypothe-
tical proteins, and the metabolic enzyme phosphocarrier
protein ptsH as interacting partners. The exact roles of
these interactions remain to be identified.
These screens were performed in a low-scale manner
with a test Cpn protein set, but generation of an Cpn
intrapathogen ‘interactome’ is conceivable through
ORFeome-wide PPI screening by automated procedures.
Likewise, a system-wide screen for host–pathogen PPIs
could be conducted by screening against other available
ORFeomes, e.g. the human ORFeome [11], which would
produce a detailed description of the host–pathogen
interface at the molecular level, leading to improved
understanding of Cpn pathogenesis in humans.
Conclusion
We achieved nearly complete cloning of the first version
of the Cpn ORFeome, and furthermore demonstrated the
feasibility of a respective expression ORFeome in the form
of recombinant protein-producing vectors and pooled
Y2H prey vectors. We showed that these collections are
functional by recombinant protein production in E. coli
and by a protein interaction assay. The availability of the
Cpn ORFeome with appropriate GatewayW-compatible
destination vectors offers many possibilities for proteome-
wide studies, including systematic Y2H PPI screenings,
and fabrication of protein chips or microarrays, which
could enable antigen-profiling for vaccination strategies
and so on. This first version of the Cpn ORFeome can be
extended in future work by addition of the missing ORFs
or inclusion of strain-specific variations.
Methods
Primer design
The DNA sequence of C. pneumoniae was obtained from
the NCBI Genome Database (NCBI; Refseq: NC_000922.1).
Primary gene-specific forward primers were designed by
adding the sequence 50-AAAAAGCAGGCTTGGAAGGA
GATAGAACCATG-30 to the 50 end of the first 20 to 30
nucleotides of each ORF. Gene-specific reverse primers
were constructed by adding the nucleotides 50-GTACAA
GAAAGCTGGGTA-30 to the 50 end of the last 20 to 30
nucleotides of the complementary strand of the ORF. The
gene-specific parts of the primary forward and reverse pri-
mers were chosen to give similar annealing temperatures
during the PCR, between 40–60°C. The 1052 primer pairs
were obtained in a 96-well format.
PCR amplification of the ORFs
As template DNA for PCR, Cpn genomic DNA was iso-
lated using a QIAampW DNA Mini Kit (Qiagen, Hilden,
Germany) from the vascular chlamydial strain CV-6,
which was recovered from chronicle vascular infection
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logical studies [35]. The 1052 PCRs were performed in
96-well plates containing 50-μl assay volumes consisting
of 1.25 U Platinum Pfx polymerase (Invitrogen), 1 mM
MgSO4, dNTP mix (0.3 mM each), primary forward and
reverse primers (0.1 μM each), secondary adapter for-
ward and reverse primers (0.4 μM each), 10× Pfx amplifi-
cation buffer (5 μl) and C. pneumoniae genomic DNA
(10 ng). The sequence of the secondary forward adapter
primer is 50-GGGGACAAGTTTGTACAAAAAAGCAG
GCTTG-30 and that of the secondary reverse adapter pri-
mer is 50-GGGGACCACTTTGTACAAGAAAGCTGGG
TA-30. After the first few cycles, enough DNA template
was produced by the primary forward and reverse pri-
mers to enable the secondary adapter primers to bind
and extend the first PCR products to generate the full-
length attB1 and attB2 sites flanking the ORFs. All 4 pri-
mers were used together in the same PCR. The 25 PCR
cycles (94°C for 30 s, 48°C for 30 s, and 72°C for 1 min/
kb) were preceded by heating to 94°C for 5 min and were
followed by a 7-min incubation at 72°C. PCR products
were used immediately without purification and then
stored at −20°C.attB × attP recombination reactions – BP reactions
The GatewayW-compatible, amplified ORFs were recom-
bined into the vector pDONRTM/Zeo (Invitrogen) by using
BP ClonaseTM II Enzyme Mix (Invitrogen). In 96-well
plates, samples containing 2 μl unpurified PCR product,
1 μl BP ClonaseTM II Enzyme Mix, 150 ng pDONRTM/
Zeo plasmid and TE buffer, pH 8.0, up to 10 μl were
incubated overnight at 25°C. After adding 1 μg protein-
ase K (Invitrogen) and incubating at 37°C for 30 min, the
BP reactions were directly used for bacterial transform-
ation. The reactions were stored at −20°C.Transformation
A 3-μl aliquot from each of the 1052 BP reactions was
added to One ShotW TOP10 chemically competent E.
coli (Invitrogen) using the manufacturer's protocol and
96-well plates. After heat-shock at 42°C for 30 s, 50 μl of
SOC medium (Invitrogen) was added to the transform-
ation reactions and the samples were incubated for 1 h
at 37°C. After the incubation, 20 μl of each sample were
plated onto low-salt LB solid medium containing 80 μg/
ml ZeocinTM (Invitrogen) and incubated overnight at
37°C to produce single colonies. The remainder of the
transformation reaction was used to inoculate 150 μl of
low-salt LB liquid medium containing 80 μg/ml Zeo-
cinTM. These cultures were also incubated at 37°C over-
night to generate transformants for long-term storage
by adding glycerol and freezing at −80°C.Colony PCR of bacterial clones
A single colony from each transformation reaction was ana-
lyzed by PCR to verify the correct size of the inserted ORF.
The 1052 PCRs were performed in 96-well plates contain-
ing 50-μl samples with 2.5 U BioThermTM Polymerase
(Genxpress, Wiener Neudorf, Austria), pDONRTM/Zeo-
specific forward primer (50-GTAAAACGACGGCCAG-30)
and reverse primer (50-CAGGAAACAGCTATGAC-30)
(0.3 μM each), dNTP mix (0.2 mM each) and 10×
BioThermTM reaction buffer (5 μl). Colonies were picked
with a sterile pipette tip and transferred to the wells of the
96-well plate. The 40 PCR cycles (94°C for 30 s, 55°C for
30 s, and 72°C for 1 min/kb) were preceded by heating to
94°C for 5 min and followed by a 7-min incubation at
72°C. The sizes of the PCR products were determined by
agarose gel electrophoresis and midori green staining.
Entry clones with inserts having the expected size were
inoculated in 150 μl low-salt LB liquid medium containing
80 μg/ml ZeocinTM and incubated overnight at 37°C to
generate glycerol long-term frozen stocks. Up to five dif-
ferent single colonies from each transformation were
screened by this PCR method till a positive single colony
was found. In cases where the PCR failed to verify a posi-
tive colony, 'pooled' entry clones were analyzed. For that,
an aliquot of the entire transformation reaction was cul-
tured in liquid LB medium overnight at 37°C. The entire
overnight culture was subjected to plasmid isolation and
tested again by PCR. Plasmid preparations from cultures
that were positive by PCR indicated the presence of cor-
rectly cloned ORFs; at worst, they consisted of a mixed
population of cells having empty plasmids and ORF-
containing plasmids.Glycerol long-term frozen stocks and plasmid preparation
Overnight cultures were mixed with glycerol to a final
glycerol concentration of 40% for long-term storage at
−80°C. Five milliliters of low-salt LB liquid medium con-
taining 80 μg/ml ZeocinTM were inoculated with 2 μl of
overnight bacterial culture. After overnight growth at
37°C, plasmids were purified with a GenEluteTM Plas-
mid Miniprep Kit (Sigma-Aldrich, St. Louis, MO,
USA), and sequenced with a pDONRTM/Zeo-specific
forward primer (50- GTTTTCCCAGTCACGAC −30).attL × attR recombination reactions – LR reactions
Entry vectors were set up in LR reactions to recombine
the gene of interest into several destination vectors. The
destination vectors used were pDESTTM15 (Invitrogen),
pBD-Gate 2, and pAD-Gate 2 [15]. The two Gate vec-
tors are in-house-generated GatewayW-compatible
pGADT7 and pGBKT7 plasmids of the MatchmakerTM
GAL4 Two-Hybrid system (Clontech, Mountain View,
CA, USA) for yeast two-hybrid analysis. Samples
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seTM II Enzyme Mix (Invitrogen), destination vector
(150 ng), and TE buffer, pH 8.0, to 10 μl were incu-
bated at 25°C overnight. After adding 1 μg proteinase K
(Invitrogen) and incubating at 37°C for 30 min, the LR
reactions were directly used for plasmid transformation
into E. coli. The reactions were stored at −20°C. Bac-
teria were transformed with the LR reactions as
described above using the appropriate antibiotic:
100 μg/ml ampicillin for pDESTTM15 and pAD-Gate2;
and 50 μg/ml kanamycin for pBD-Gate2. Colony PCRs
were performed as described above to verify the suc-
cessful cloning by using vector-specific primers. The
expression clones were prepared using a GenEluteTM
Plasmid Miniprep Kit (Sigma-Aldrich).Recombinant protein production
Prepared pDESTTM15 expression vectors harboring the
desired ORFs were used to transform chemically compe-
tent E. coli BL21(DE3) (Invitrogen), and the cells were
plated onto LB solid medium containing 100 μg/ml
ampicillin. Single colonies from each plate were used to
inoculate 5 ml LB liquid medium containing 100 μg/ml
ampicillin. Cells were grown overnight at 37°C and pro-
tein expression was induced the next day by inoculating
the whole overnight culture into 50 ml fresh medium
containing 100 μg/ml ampicillin and IPTG (1 mM) and
incubating for a further 4 h. The cells were lysed and
protein expression was shown by SDS-PAGE and coo-
massie staining. The proteins were further analysed by
standard western blot procedures. The primary antibody
was the commercially available mouse anti-GST (B-14)
(sc-138 B; Santa Cruz Biotechnology, Santa Cruz, CA).
For detection, an HRP conjugated polyclonal rabbit anti-
Mouse antibody (P0161; Dako, Glostrub, Denmark) was
used.Genome-wide Y2H screening
As a functional test of our C. pneumoniae ORFeome library,
we shuttled all entry clones into the GatewayW-compatible
Y2H destination vector pAD-Gate2 to serve as a prey library
in a screen for interactions with three proteins, two of them
involved in Type III secretion (see below). To construct the
library, all plasmid preparations of entry clones were pooled
together and 2 μl of the pooled entry library were used in a
standard LR reaction with pAD-Gate2. To construct the
bait molecules, entry clones encoding the full-length genes
flhA (CPn0363), fliF (CPn0860) and EUO (CPn0561) were
shuttled into the GAL4 DNA-binding domain (BD)-con-
taining vector pBD-Gate2 [15], and sequenced. In an add-
itional experiment, in which the known interaction between
p53 and SV40 large T antigen [36] served as a positive con-
trol, the constructs were found to have no capacity to non-specifically activate reporter genes. The prey library and the
bait were used simultaneously to co-transform the haploid
Saccharomyces cerevisiae strain AH109 (genotype: MATa,
trp1-901, leu2-3, 112, ura3-52, his3-200, gal4Δ, gal80Δ,
LYS2:: GAL1UASGAL1TATA-HIS3, GAL2UAS-GAL2TATA ADE2;
URA3::MEL1UAS-MEL1TATA-lacZMEL1) according to a
standard high-efficiency lithium acetate method, and finally
plated onto (i) a nutritionally selective medium deficient in
tryptophan and leucine (SD/-leu-trp) to test for positive
plasmid uptake and general transformation efficiency, and
(ii) SD/-trp-leu-ade-his synthetic medium to select for ac-
tual reporter activity. The plates were incubated for at least
4 days at 28°C. The prey library vectors from primary posi-
tive yeast candidate clones were recovered by plasmid isola-
tion via digestion with 10 U lyticase (Sigma-Aldrich),
addition of 10% SDS, one freeze-thaw cycle, and purification
by using a WizardW SV gel and PCR clean-up system (Pro-
mega, Madison, WI, USA). The plasmids were then ampli-
fied in E. coli DH5α cells and reintroduced back into the
yeast strain AH109 together with the bait or empty pBD-
Gate2 (as a control) and finally retested on SD/-trp-leu-ade-
his in order to verify their reporter activity before the se-
quence of the clone was determined by using vector-specific
primers. Bioinformatical analyses were conducted through
the National Center for Biotechnology Information (NCBI)
by using the basic local alignment search tool (BLAST) ac-
cessible via http://blast.ncbi.nlm.nih.gov/Blast.cgi, the
ExPASy Proteomics Server (http://www.expasy.ch/), the
Universal Protein Resource UniProt (www.uniprot.org/) and
the SWISS-PROT knowledgebase (http://expasy.org/sprot/).
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